Inventor · disambiguated record
Gunnar Nordvall
Also filed as: NORDVALL GUNNAR
20 granted patents·17 pending applications·75 citations·filing 1993–2024
93Inventor score
Top patents by PatentIndex Score
37 records- 0183US12209071B2Triazine derivatives for treating diseases relating to neurotrophinsAlzeCure Pharma AB·Filed 2022·Granted Jan 28, 2025·1 cites·32 claims
- 0282US9822075B2NMDA antagonist prodrugsASTRAZENECA AB·Filed 2014·Granted Nov 21, 2017·3 cites·12 claims
- 0379US11352332B2Triazine derivatives for treating diseases relating to neurotrophinsAlzeCure Pharma AB·Filed 2019·Granted Jun 7, 2022·1 cites·2 claims
- 0479US8163928B2Heteroaryl substituted benzothiazolesGRAVENFORS YLVA·Filed 2007·Granted Apr 24, 2012·7 cites·10 claims
- 0577US8367676B22-carboxamide-7-piperazinyl-benzofuran derivatives 774ASTRAZENECA AB·Filed 2010·Granted Feb 5, 2013·5 cites·6 claims
- 0677US7947693B25,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitorsASTRAZENECA AB·Filed 2006·Granted May 24, 2011·3 cites·8 claims
- 0776US5599937AHeteroaromatic quinuclidinenes, their use and preparationPHARMACIA AB·Filed 1993·Granted Feb 4, 1997·38 cites·11 claims
- 0874US2025214948A1Triazine derivatives for treating diseases relating to neurotrophinsAlzeCure Pharma AB·Filed 2024·Application pending·0 cites
- 0971US7960395B25,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptorsASTRAZENECA AB·Filed 2007·Granted Jun 14, 2011·1 cites·20 claims
- 1070US7067657B2Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptorASTRAZENECA AB·Filed 2002·Granted Jun 27, 2006·8 cites·1 claims
- 1169US10815199B2NMDA antagonist prodrugsASTRAZENECA AB·Filed 2019·Granted Oct 27, 2020·0 cites·15 claims
- 1269US8859534B22-carboxamide-7-piperazinyl-benzofuran derivativesASTRAZENECA AB·Filed 2013·Granted Oct 14, 2014·2 cites·11 claims
- 1369US8158785B25,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapyJOHANSSON ROLF·Filed 2007·Granted Apr 17, 2012·1 cites·18 claims
- 1469US8088780B25,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptorsNORDVALL GUNNAR·Filed 2006·Granted Jan 3, 2012·2 cites·10 claims
- 1568US11840524B24-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptorsAlzeCure Pharma AB·Filed 2019·Granted Dec 12, 2023·1 cites·33 claims
- 1667US8957215B2Heteroaryl substituted benzothiazolesGRAVENFORS YLVA·Filed 2012·Granted Feb 17, 2015·1 cites·29 claims
- 1762US9145380B2Bis-(sulfonylamino) derivatives for use in therapyBYLUND JOHAN·Filed 2008·Granted Sep 29, 2015·1 cites·14 claims
- 1861US10207994B2NMDA antagonist prodrugsASTRAZENECA AB·Filed 2017·Granted Feb 19, 2019·0 cites·4 claims
- 1956US2011021540A1Bis-(Sulfonylamino) Derivatives in Therapy 066ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2056US2009281138A1Bis-(Sulfonylamino) Derivatives in Therapy 066ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2153US2009163586A1Bis-(Sulfonylamino) Derivatives in Therapy 205ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2252US8236951B2Thioxanthine derivatives as myeloperoxidase inhibitorsHANSON SVERKER·Filed 2008·Granted Aug 7, 2012·0 cites·1 claims
- 2350US2009247555A15,7-Disubstituted[1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 258ASTRAZENECA AB·Filed 2009·Application pending·0 cites
- 2448US2009131468A1Bis-(Sulfonylamino) Derivatives in Therapy 065ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2545US2007142386A1New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1ASTRAZENECA·Filed 2004·Application pending·0 cites
- 2644US9440992B25,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitorsNORDVALL GUNNAR·Filed 2010·Granted Sep 13, 2016·0 cites·8 claims
- 2743US2022324819A1Triazine derivatives for treating diseases relating to neurotrophinsAlzeCure Pharma AB·Filed 2020·Application pending·0 cites
- 2843US2011105537A15,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptorsASTRAZENECA AB·Filed 2011·Application pending·0 cites
- 2943US2009054453A1Novel Tetralins as 5-HT6 ModulatorsALCARAZ LILIAN·Filed 2007·Application pending·0 cites
- 3042US2005004130A1New metabotropic glutamate receptor compoundsASTRAZENECA AND NPS PHARMACEUT·Filed 2004·Application pending·0 cites
- 3142US2010173890A1Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's DiseaseASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3238US2009099187A1Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 ReceptorASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3337US9611254B2Triazole compounds and their use as gamma secretase modulatorsActurum Life Science AB·Filed 2014·Granted Apr 4, 2017·0 cites·19 claims
- 3437US2020113910A1Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinasesAlzeCure Pharma AB·Filed 2017·Application pending·0 cites
- 3537US2021261513A14-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptorsAlzeCure Pharma AB·Filed 2019·Application pending·0 cites
- 3637US2009030038A1Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 ReceptorASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3736US2010105657A1Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's DiseaseASTRAZENECA AB·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gunnar Nordvall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →